Empagliflozin achieves control of HbA1c and various phase III weight loss
Dialogue between cells that secrete insulin and tissues in the brain, liver, fat and muscle are now considered key to understanding diabetes. As pointed out by Ramón Gomis, director of the biomedical research institute August Pi i Sunyer of Barcelona, in practice this knowledge allows to approach the disease with new drugs, which, when exerting its action in a certain tissue, also has an impact on other tissues. "There are new molecules that, acting either on the loss of glucose by the urine, at the central level in the pituitary gland, or in the digestive tract, have a very important impact on the function of secretory cells," he adds.
In this sense, one of the drugs that allows excess glucose to be excreted through the urine by reducing the reabsorption of glucose in the kidney is empagliflozin, an investigational sodium-glucose-type 2 (SGLT2) inhibitor under investigation, developed by Boehringer Ingelheim-Lilly Alliance.
According to the results of a 24-week phase III study of 899 patients presented at the ADA Congress, which analyzes empagliflozin with two doses (10mg and 25mg) as monotherapy, the treatment achieves statistically significant reductions in levels of glycosylated hemoglobin (HbA1c) Versus placebo in patients with T2DM who had not received any treatment for at least 12 weeks prior to randomization.
Also, after 24 weeks, a weight-adjusted placebo reduction was observed. Specifically, 1.93 kilos with the dose of 10mg and 2.15 kilos with the superior.
In terms of changes in diastolic blood pressure, the reduction was statistically significant in the empagliflozin arm 25mg (1.9mmHg) versus 0.5mmHg with placebo.
Gomis points out that the main advantage of this drug is that its effect is independent of the cause (if there is insulin resistance or beta cell deficits) or the time of diabetic disease.
In addition, empagliflozin is also proving to be effective associated with other drugs.
Thus, two other Phase III studies presented in ADA have also demonstrated the efficacy and safety of empagliflozine as an antidiabetic treatment complementary to metformin with or without the addition of sulphonylurea and empagliflozin in combination with insulin.
Randomized, double-blind, placebo-controlled trials at doses of 10mg and 25mg of empagliflozin showed a reduction in HbA1c levels as well as statistically significant decreases in body weight. In the case of empagliflozine in combination with metformin, without sulfonylurea, and empagliflozin in combination with insulin, an analysis shows reductions in systolic blood pressure compared to placebo.
In this sense, one of the drugs that allows excess glucose to be excreted through the urine by reducing the reabsorption of glucose in the kidney is empagliflozin, an investigational sodium-glucose-type 2 (SGLT2) inhibitor under investigation, developed by Boehringer Ingelheim-Lilly Alliance.
According to the results of a 24-week phase III study of 899 patients presented at the ADA Congress, which analyzes empagliflozin with two doses (10mg and 25mg) as monotherapy, the treatment achieves statistically significant reductions in levels of glycosylated hemoglobin (HbA1c) Versus placebo in patients with T2DM who had not received any treatment for at least 12 weeks prior to randomization.
Also, after 24 weeks, a weight-adjusted placebo reduction was observed. Specifically, 1.93 kilos with the dose of 10mg and 2.15 kilos with the superior.
In terms of changes in diastolic blood pressure, the reduction was statistically significant in the empagliflozin arm 25mg (1.9mmHg) versus 0.5mmHg with placebo.
Gomis points out that the main advantage of this drug is that its effect is independent of the cause (if there is insulin resistance or beta cell deficits) or the time of diabetic disease.
In addition, empagliflozin is also proving to be effective associated with other drugs.
Thus, two other Phase III studies presented in ADA have also demonstrated the efficacy and safety of empagliflozine as an antidiabetic treatment complementary to metformin with or without the addition of sulphonylurea and empagliflozin in combination with insulin.
Randomized, double-blind, placebo-controlled trials at doses of 10mg and 25mg of empagliflozin showed a reduction in HbA1c levels as well as statistically significant decreases in body weight. In the case of empagliflozine in combination with metformin, without sulfonylurea, and empagliflozin in combination with insulin, an analysis shows reductions in systolic blood pressure compared to placebo.
Comments
Post a Comment